Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SLS |
---|---|---|
09:32 ET | 21522 | 1.1801 |
09:33 ET | 6690 | 1.16 |
09:35 ET | 2542 | 1.15 |
09:37 ET | 1500 | 1.165 |
09:39 ET | 2300 | 1.165 |
09:42 ET | 600 | 1.175 |
09:44 ET | 544 | 1.165 |
09:46 ET | 6115 | 1.16 |
09:48 ET | 3100 | 1.16 |
09:50 ET | 18063 | 1.145 |
09:51 ET | 1299 | 1.145 |
09:53 ET | 3319 | 1.1484 |
09:55 ET | 888 | 1.1473 |
09:57 ET | 499 | 1.1594 |
10:00 ET | 1507 | 1.1504 |
10:02 ET | 2800 | 1.16 |
10:04 ET | 500 | 1.155 |
10:06 ET | 3250 | 1.1599 |
10:09 ET | 200 | 1.155 |
10:13 ET | 600 | 1.155 |
10:15 ET | 1200 | 1.1585 |
10:18 ET | 10500 | 1.155 |
10:20 ET | 200 | 1.155 |
10:22 ET | 100 | 1.155 |
10:24 ET | 11563 | 1.15 |
10:26 ET | 6341 | 1.15 |
10:27 ET | 400 | 1.15 |
10:29 ET | 200 | 1.15 |
10:31 ET | 1299 | 1.15 |
10:33 ET | 100 | 1.15 |
10:36 ET | 3600 | 1.1536 |
10:38 ET | 2200 | 1.15 |
10:40 ET | 818 | 1.155 |
10:44 ET | 100 | 1.15 |
10:45 ET | 1200 | 1.155 |
10:47 ET | 250 | 1.1591 |
10:51 ET | 2368 | 1.1599 |
10:54 ET | 300 | 1.155 |
10:56 ET | 500 | 1.15 |
10:58 ET | 11252 | 1.145 |
11:00 ET | 950 | 1.1499 |
11:02 ET | 15868 | 1.145 |
11:12 ET | 168 | 1.15 |
11:14 ET | 250 | 1.15 |
11:16 ET | 600 | 1.155 |
11:18 ET | 6110 | 1.155 |
11:20 ET | 800 | 1.155 |
11:21 ET | 400 | 1.155 |
11:23 ET | 2700 | 1.155 |
11:25 ET | 1300 | 1.155 |
11:32 ET | 5062 | 1.155 |
11:34 ET | 263 | 1.155 |
11:36 ET | 200 | 1.155 |
11:38 ET | 200 | 1.155 |
11:39 ET | 1000 | 1.15 |
11:41 ET | 500 | 1.155 |
11:45 ET | 300 | 1.1509 |
11:50 ET | 250 | 1.16 |
11:52 ET | 600 | 1.1598 |
12:01 ET | 28099 | 1.165 |
12:03 ET | 12125 | 1.165 |
12:06 ET | 4328 | 1.155 |
12:12 ET | 600 | 1.1501 |
12:19 ET | 4284 | 1.155 |
12:24 ET | 1249 | 1.155 |
12:28 ET | 700 | 1.1506 |
12:30 ET | 100 | 1.155 |
12:42 ET | 2323 | 1.155 |
12:44 ET | 100 | 1.155 |
12:46 ET | 948 | 1.1508 |
12:50 ET | 3103 | 1.155 |
12:51 ET | 2900 | 1.165 |
12:55 ET | 2100 | 1.165 |
12:57 ET | 900 | 1.1609 |
01:00 ET | 3025 | 1.16 |
01:04 ET | 15285 | 1.155 |
01:09 ET | 199 | 1.15 |
01:11 ET | 3150 | 1.1599 |
01:24 ET | 408 | 1.16 |
01:27 ET | 9251 | 1.165 |
01:31 ET | 3000 | 1.16 |
01:33 ET | 500 | 1.165 |
01:38 ET | 200 | 1.17 |
01:44 ET | 900 | 1.17 |
01:45 ET | 1000 | 1.1692 |
01:49 ET | 3600 | 1.1699 |
01:56 ET | 1000 | 1.1692 |
02:03 ET | 300 | 1.165 |
02:09 ET | 100 | 1.165 |
02:12 ET | 111 | 1.165 |
02:14 ET | 100 | 1.165 |
02:18 ET | 222 | 1.165 |
02:21 ET | 111 | 1.165 |
02:23 ET | 11689 | 1.17 |
02:25 ET | 100 | 1.175 |
02:27 ET | 4800 | 1.175 |
02:32 ET | 3700 | 1.18 |
02:34 ET | 2300 | 1.175 |
02:36 ET | 100 | 1.18 |
02:38 ET | 8241 | 1.17 |
02:39 ET | 1400 | 1.17 |
02:41 ET | 15002 | 1.175 |
02:45 ET | 3300 | 1.17 |
02:48 ET | 299 | 1.18 |
02:50 ET | 7700 | 1.165 |
02:52 ET | 2500 | 1.165 |
02:54 ET | 1712 | 1.164719 |
02:59 ET | 100 | 1.165 |
03:03 ET | 300 | 1.165 |
03:08 ET | 1500 | 1.1653 |
03:10 ET | 200 | 1.165 |
03:21 ET | 150 | 1.1613 |
03:24 ET | 150 | 1.16 |
03:26 ET | 3203 | 1.1695 |
03:28 ET | 10573 | 1.17 |
03:30 ET | 400 | 1.17 |
03:32 ET | 500 | 1.165 |
03:35 ET | 184 | 1.165 |
03:39 ET | 250 | 1.165 |
03:46 ET | 1000 | 1.17 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Sellas Life Sciences Group Inc | 76.6M | -1.3x | --- |
ALX Oncology Holdings Inc | 76.4M | -0.4x | --- |
Monopar Therapeutics Inc | 77.2M | -7.3x | --- |
RAPT Therapeutics Inc | 77.8M | -0.7x | --- |
IO Biotech Inc | 79.1M | -0.8x | --- |
Aerovate Therapeutics Inc | 80.5M | -0.9x | --- |
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $76.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 64.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.44 |
EPS | $-0.93 |
Book Value | $-0.25 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.